The Federal Trade Commission is suing to block biopharma giant Amgen Inc.’s AMGN proposed acquisition of Horizon Therapeutics PLC HZNP, saying the deal would allow Amgen to “entrench the monopoly positions” of Horizon treatments for two serious medical conditions.
By acquiring Horizon, Amgen could use rebates on its blockbuster drugs to pressure insurance companies and pharmacy benefit managers to favor Horizon treatments for thyroid eye disease and chronic refractory gout, the FTC said. Those treatments, Tepezza and Krystexxa, have no competitors, the agency said.
The proposed $27.8 billion deal, announced late last year, is the largest pharmaceutical transaction announced in 2022, the FTC said. Amgen made a commitment not to “bundle,” or offer multiproduct discounts tied to the Horizon products at issue in the FTC complaint, the company said in its statement. Horizon said in a statement that it also has no plans to bundle any of its rare-disease treatments and that the deal “has the potential to accelerate the availability of important rare disease medicines to more patients worldwide.”
Portugal Últimas Notícias, Portugal Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Fonte: CNBC - 🏆 12. / 72 Consulte Mais informação »
Fonte: ChicagoBreaking - 🏆 521. / 51 Consulte Mais informação »